articleCancer ResearchMar 1, 2005Closed access

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Okayama University · Center for Neuro-Oncology · +5 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or…

Citation impact

675
total citations
FWCI
37.61
Percentile
100%
References
29
Citations per year

Authors

13

Topics & keywords

Keywords
  • KRAS
  • Adenocarcinoma
  • Cancer research
  • Epidermal growth factor receptor
  • Tyrosine kinase
  • Biology
  • Receptor tyrosine kinase
  • Mutation
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.